Menu

How Blood Cells Thwart Malaria

The sickle cell anemia mutation may protect against malaria by preventing the parasite from sending dangerous proteins to the red blood cell surface.

Nov 10, 2011
Tia Ghose

Sickle cells infected with malaria stained with green flourescent proteinSCIENCE/AAAS

Two hemoglobin mutations, including one that causes sickle cell anemia, may protect people from severe malaria by gumming up the cellular machinery the parasite uses to transmit deadly proteins to the cell surface. The findings, published today (November 10) in Science Express, suggest potential ways to fight the deadly disease.

“It’s a great study,” said Rick Fairhurst, who studies malaria pathogenesis and immunity at the National Institute of Allergy and Infectious Diseases, and was not involved in the study. “It really takes us a huge, giant leap forward.” By showing what mutations enable cells to avoid the deadliest consequences of malaria, the research may also point to potential treatment targets, he added.

For decades, researchers have known that people who carry a gene for sickle cell anemia are highly resistant to dying from malaria. Research has shown that it is the mutation to one of their hemoglobin genes, which codes for the oxygen-transporting protein in red blood cells, that was responsible for the fortuitous effect, and that other mutations in that same gene were also protective. But despite years of research, no one knew why.

Fairhurst and his colleagues published a paper showing that compared to normal cells, red blood cells carrying two hemoglobin mutations had lower surface concentrations of a virulent, sticky protein produced by the malaria parasite, Plasmodium falciparum. The protein, which is normally shuttled from the parasite’s protein making factory inside the cells to the cell surface, prevents the body from clearing infected blood cells. But in the blood cells with mutated hemoglobin, that didn’t seem to happen—the parasite proteins never made it to the surface of the cells.

To find out why, parasitologist Michael Lanzer of Heidelberg University in Germany and his colleagues flash froze red blood cells with and without the mutations and used electron microscopy to visualize the cells before and after infection.

They found that uninfected cells contained short pieces of actin that help keep the membrane skeleton rigid. After infection, in normal cells, long actin filaments appeared, linking a cellular component made by the parasite called the Maurer’s cleft, which looks a bit like a stack of pancakes, to the cell membrane. “We concluded that the parasite mines that actin from the membrane skeleton of the host, and uses this mined actin to generate actin filaments of its own design,” Lanzer said—namely to transmit the proteins to the outside surface of the red blood cell.

By contrast, in cells with mutated hemoglobin, the Maurer’s cleft looked more like a big blob and the disordered actin filaments did not connect the cleft to the cell membrane. Somehow, it seemed, the mutations were preventing the parasite from setting up its protein factory effectively, thereby reducing protein transport outside the cell.

The team also took a closer look at the hemoglobin, and found that  the difference between the mutated and wild-type cells was that mutated forms were more easily oxidized.  When they placed actin filaments in the presence of both the normal and mutated copies of hemoglobin, the researchers found that mutated forms of hemoglobin led to shorter actin chains than wild-type hemoglobin. Actin placed with oxidized hemoglobin similarly failed to form long chains, suggesting that oxidation was indeed responsible for the difference in the parasite’s protein machinery seen in cells with mutated and normal hemoglobin.

Taken together, the findings suggest that the hemoglobin mutations blunt the deadliness of malaria because the oxidized hemoglobin inhibits actin reorganization, thereby preventing the malaria parasite from shuttling its proteins to the surface red blood cells, Lanzer said.

Future work should confirm that the same effects are seen in cells that carry only one copy of the mutated hemoglobin, since the vast majority of people who carry these mutations and have a survival advantage against malaria are heterozygous for the mutated hemoglobin, Fairhurst said.

Understanding how the body gets around malaria’s deadliness could guide the design of drug therapies, he added, for instance by finding small molecules that inhibit the parasite’s protein trafficking machinery.

“Mother Nature had 10,000 years or so to mutate the genome in ways that would actually protect against death,” Fairhurst said. “We want to use these mutations to teach us something about how you protect children.”

M. Cyrklaff, et. al, “"Hemoglobins S and C interfere with Actin Remodeling in Plasmodium falciparum-Infected Erythrocytes," Science Express, doi:10.1126/science.1213775, 2011.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.